Author Affiliations: Departments of Dermatology, Philipps University, Marburg, Germany (Dr Hertl), University of Reims, France (Dr Bernard), and Inselspital-University of Bern, Switzerland (Dr Borradori).
In this issue of the Archives, Le Roux-Villet et al1 describe 25 patients with mucous membrane pemphigoid (MMP) who had either extensive disease for a mean of 32 months, ie, progressive eye and/or oral/tracheal involvement or were refractory to the initially applied immunosuppressive or immunomodulatory drugs. The cohort of patients with MMP had either ocular (n = 10) and/or extraocular involvement (n = 15) and received 1 or 2 cycles of rituximab (each cycle consisting of rituximab, 4 × 375 mg/m2 administered intravenously at weekly intervals). After the first rituximab cycle, a total of 68% (17 of 25) of patients with MMP experienced complete clinical remission within 12 weeks, while an additional 5 of 25 patients required a second cycle of rituximab to achieve clinical remission. Overall, only 3 of 25 patients (12%) did not experience clinical remission with rituximab treatment. Most of the patients did not continue adjuvant immunosuppressive drugs and received only concomitant immunomodulatory treatment with dapsone or sulfasalazine during rituximab treatment. Of the 22 patients in complete remission, 10 developed a clinical relapse within 4 months, suggesting a short-lived effect of rituximab. Of note, 3 of 25 patients (12%) developed severe infections within 4 months after rituximab treatment and 2 patients died.
Hertl M, Bernard P, Borradori L. Rituximab for Severe Mucous Membrane PemphigoidSafe Enough to Be Drug of First Choice?. Arch Dermatol. 2011;147(7):855–856. doi:10.1001/archdermatol.2011.167
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.